Trial Profile
A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin (Terlipressin) (The REVERSE Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Terlipressin (Primary)
- Indications Hepatorenal syndrome
- Focus Registrational; Therapeutic Use
- Acronyms REVERSE
- Sponsors Ikaria; Mallinckrodt plc
- 14 Nov 2023 Results assessing Decision-Analytic Model to Project the Benefit of Terlipressin Treatment Among Patients with Alcohol-Related Cirrhosis and Hrs using using data from this study presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Results of pooled subgroup analysis (n=598) assessing Improved Mean Arterial Pressure from Baseline to the End of Treatment with Terlipressin is Associated with Hepatorenal Syndrome Reversal presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Results of pooled analysis from two trials (CONFIRM-NCT02770716 and REVERSE-NCT01143246), presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.